F-group (family)
4004.1.1.3 NAD_kinase_C
Ligands and drugs
778
Member domains
150
with ligand contacts (≤ 4 Å)
19.3% of members
123
with DrugDomain annotations
15.8% of members
108
with a DrugBank compound
13.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 4004.1.1.3 belongs to X-group 4004 NAD kinase beta sandwich domain-like, which has 12 proteins with classified ligands. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03461 | NAP | Nicotinamide adenine dinucleotide phosphate | 12 |
| DB14128 | NAD | Nadide | 8 |
| DB00171 | ATP | ATP | 4 |
| DB00157 | NAI | NADH | 2 |
| DB02282 | MTA | 5'-S-methyl-5'-thioadenosine | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 12 |
| NAP | NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE | 12 |
| 5A8 | 5'-azido-5'-deoxy-8-[(2-{[2-(1H-indol-3-yl)ethyl]amino}-2-oxoethyl)sulfanyl]adenosine | 4 |
| 5A9 | 5'-azido-8-[(2-{[2-(3-bromophenyl)ethyl]amino}-2-oxoethyl)sulfanyl]-5'-deoxyadenosine | 4 |
| 5AG | 5'-azido-5'-deoxy-8-[(2-{[2-(3-ethynylphenyl)ethyl]amino}-2-oxoethyl)sulfanyl]adenosine | 4 |
| 5AJ | 5'-azido-8-[(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}-2-oxoethyl)sulfanyl]-5'-deoxyadenosine | 4 |
| 5AK | 8-[(2-{[2-(3-bromophenyl)ethyl]amino}-2-oxoethyl)sulfanyl]adenosine | 4 |
| 5AQ | 8-({2-oxo-2-[(2-phenylethyl)amino]ethyl}sulfanyl)adenosine | 4 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 4 |
| IOD | IODIDE ION | 4 |
| UNX | UNKNOWN ATOM OR ION | 4 |
| 5NB | 5'-amino-8-bromo-5'-deoxyadenosine | 2 |
| DTA | (2S,3S,4R,5R,2'S,3'S,4'R,5'R)-2,2'-[DITHIOBIS(METHYLENE)]BIS[5-(6-AMINO-9H-PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL] | 2 |
| MTA | 5'-DEOXY-5'-METHYLTHIOADENOSINE | 2 |
| NAI | 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE | 2 |
| OWU | (1~{R},23~{R},24~{S},25~{R})-14-[[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl]-7-azanyl-24,25-bis(oxidanyl)-20,20-bis(oxidanylidene)-26-oxa-20$l^{6}-thia-2,4,6,9,14,17,21-heptazatetracyclo[21.2.1.0^{2,10}.0^{3,8}]hexacosa-3,5,7,9-tetraen-11-yn-16-one | 2 |
| 5CI | 8-bromo-5'-{[3-carboxy-2-(carboxymethyl)-2-hydroxypropanoyl]amino}-5'-deoxyadenosine | 1 |
| 5N5 | 5'-amino-5'-deoxyadenosine | 1 |
| A22 | [(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHYL[(2R,3R,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3-HYDROXY-4-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL DIHYDROGEN DIPHOSPHATE | 1 |
| A2D | BIS{[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHYL} DIHYDROGEN DIPHOSPHATE | 1 |